Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial

Anne Sophie Sølling, Torben Harsløf, Bente Langdahl, Anne Sophie Sølling, Torben Harsløf, Bente Langdahl

Abstract

Discontinuing denosumab is associated with bone loss and possibly increased fracture risk. We investigated if treatment with zoledronate (ZOL) could prevent bone loss and if the timing of the ZOL infusion influenced the outcome. We report on a 2-year randomized, open label, interventional study including 61 patients with osteopenia, discontinuing denosumab after 4.6 ± 1.6 years. We administrated ZOL 6 months (6M group, n = 20) or 9 months (9M group, n = 20) after the last denosumab injection or when bone turnover had increased (OBS group, n = 21). We monitored the patients with DXA and bone turnover markers. Our primary endpoints were change in lumbar spine BMD (LSBMD) 6 months after ZOL and the proportion of patients who failed to maintain BMD. The study is ongoing (clinicaltrials.gov; NCT03087851). We included 61 participants and 59 patients completed follow-up 12 months after ZOL. Six months after ZOL, LSBMD had decreased significantly by (mean ± SE) 2.1% ± 0.9%, 4.3% ± 1.1%, and 3.0% ± 1.1% in the 6M, 9M, and OBS groups, respectively, and by 4.8% ± 0.7%, 4.1% ± 1.1%, and 4.7% ± 1.2% 12 months after ZOL in the 6M, 9M, and OBS groups, respectively (p < .02, no between-group differences). BMD loss above the least significant change was seen in all groups; at the spine: 6M, n = 6 (30%); 9M, n = 9 (45%); and OBS, n = 9 (47%); and at the total hip: 6M, n = 1 (5%); 9M, n = 5 (25%); and OBS, n = 2 (11%). In the 6M group p-crosslinked C-terminal telopeptide (p-CTX) decreased initially, but increased rapidly thereafter, and 6 months after ZOL, p-CTX was 0.60 ± 0.08 g/L. p-CTX increased rapidly in the 9M and OBS groups, was suppressed by ZOL but increased again thereafter; p-CTX was 0.47 ± 0.05 μg/L and 0.47 ± 0.05 μg/L in the 9M and OBS groups 6 months after ZOL, respectively. Incident vertebral fractures were seen in two women in the 9M group. Treatment with ZOL irrespective of the timing did not fully prevent loss of BMD in patients discontinuing denosumab. © 2020 American Society for Bone and Mineral Research.

Keywords: ANTIRESORPTIVES; BIOCHEMICAL MARKERS OF BONE TURNOVER; CLINICAL TRIAL; DXA; OSTEOPOROSIS.

© 2020 American Society for Bone and Mineral Research.

References

    1. Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401-19.
    1. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-23.
    1. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222-9.
    1. Bone HG et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972-80.
    1. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after Denosumab discontinuation: systematic review and additional cases. J. Bone Miner. Res. 2017;32(6):1291-6.
    1. Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab - from clinic and biomechanics. Osteoporos Int. 2016;27(5):1917-21.
    1. Cummings SR et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190-8.
    1. Ferrari S et al. Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment. J Bone Miner Res. 2019;34(6):1033-40.
    1. Black DM et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243-54.
    1. Reid IR, Horne AM, Mihov B, Gamble GD. Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int. 2017;101(4):371-4.
    1. Harsløf T et al. Rosiglitazone decreases bone mass and bone marrow fat. J. Clin. Endocrinol. Metab. 2011;96(5):1541-8.
    1. Freemantle N et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317-26.
    1. Kendler D et al. Bone mineral density after transitioning from denosumab to alendronate’. J. Clin. Endocrinol. Metab. 2019;105(3):e255-e264.
    1. Lehmann T, Aeberli D. Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures. Osteoporos. Int. 2017;28(10):3067-8.
    1. Horne AM, Mihov B, Reid IR. Bone loss after romosozumab/denosumab: effects of bisphosphonates. Calcif. Tissue Int. 2018;103(1):55-61.
    1. Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T. A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J. Bone Miner. Res. 2020.
    1. Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Miner. Res. 2019;34(12):2220-2228.
    1. Horne AM, Mihov B, Reid IR. Effect of zoledronate on bone loss after romosozumab/denosumab: 2-year follow-up. Calcif. Tissue Int. 2019;105(1):107-108.
    1. Anastasilakis AD et al. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur. J. Endocrinol. 2017;176(6):677-83.
    1. Eastell R, Vittinghoff E, Lui LY, et al. Surrogate threshold effect: a novel approach for potential approval of new osteoporosis treatments using change in BMD. Study-level analysis from the FNIH Bone Quality Project. J Bone Miner Res. 2019;32 Suppl 1. [Presented orally at: Annual Meeting American Society for Bone and Mineral Research (ASBMR); 2019 Sep 20-23; Orlando, FL, USA; Presentation Number: 1090]. Available from: .

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다